Verastem Stock Surges 11% Before FDA Kidney Drug Decision, 35% Upside
VERA•Verastem Therapeutics shares jumped 11% on Thursday, trading at more than double average volume as investors bet on a July PDUFA decision for its lead kidney disease drug. Retail analysts forecast a 35% stock upside if the therapy wins approval, highlighting potential access to the $2 billion kidney disease market.
1. Stock Rally
Verastem Therapeutics shares rose 11% on Thursday, more than doubling average daily trading volume as investors positioned ahead of a key FDA decision on its lead kidney disease therapy.
2. FDA Decision
The FDA's PDUFA action date for the company's first-in-class chronic kidney disease candidate is scheduled for early July, determining whether the drug can proceed toward commercial launch.
3. Analyst Outlook
Retail analysts raised price targets by an average of 35% based on an approval scenario, reflecting significant upside to current consensus valuation models.
4. Market Opportunity
The therapy targets the multi-billion-dollar kidney disease market, where approval could unlock strategic partnerships, milestone payments and early revenue streams.
